Author

Ali Afrasiabi

UNSW SydneyORCID 0000-0003-3500-4346Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Approach:statistical model· 2 Assay:whole-genome sequencing· 2 Research Focus:benchmarking· 1 Research Focus:differential expression· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1

Frequent Co-Authors

Hamid Alinejad‐RoknyiD· 2 shared Cara E. ToscaniD· 1 shared Carl R. WalkleyiD· 1 shared Chowdhury Hasan Sarowar· 1 shared Christopher J. JollyiD· 1 shared David Alexander BrowniD· 1 shared David Richmond BoothiD· 1 shared Diako EbrahimiiD· 1 shared

Activity by Year

2018-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMolecular Biology

Hamid Alinejad‐RoknyORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Molecular BiologybioRxivPreprintApr 17, 2024

Genome-Wide CRISPR-Cas9 Screening Identifies a Synergy between Hypomethylating Agents and SUMOylation Blockade in MDS/AML

Peter Truong, Sylvie Shen, Swapna Mahurkar Joshi…·John E. Pimanda

This study identifies a synergy between hypomethylating agents and SUMOylation blockade in MDS/AML using CRISPR-Cas9 screening, showing improved therapeutic outcomes in xenograft models.

DOI 10.1101/2024.04.17.589858

humanwhole-genome sequencing

𝕏 PostBluesky

GenomicsbioRxivPreprintOct 23, 2020

Insight into the origin of 5UTR and source of CpG reduction in SARS-CoV-2 genome

Ali Afrasiabi, Hamid Alinejad‐Rokny, Nigel Hamilton Lovell…·Diako Ebrahimi

The paper investigates the origin of SARS-CoV-2 genome and the source of its low CpG content, finding evidence of recombination between bat and pangolin coronaviruses and ruling out ZAP as the cause of CpG reduction.

1 citation

statistical model

𝕏 PostBluesky

GenomicsbioRxivPreprintAug 13, 2018

Genetic evidence that the latency III stage of Epstein-Barr Virus infection is a therapeutic target for Multiple Sclerosis

Ali Afrasiabi, Grant Peter Parnell, Nicole Fewings…·David Richmond Booth

The paper identifies EBV latency III stage as a therapeutic target for MS by linking MS risk SNPs to EBV transcription factors and miRNAs.

1 citation

humanDNA methylation

𝕏 PostBluesky